Rss Top Picks FeedRss Daily Feed| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
| There are 5 registered members and 70 guests viewing the site. | Follow us on Twitter | Rss Top Picks Feed | Rss Daily Feed |
|
| DON'T BUY | 37.480 | Don Lato | This one is going nowhere fast. Declining earnings. Just had a big drug, Prexus, come off patent, which accounted for 11% of their sales. No new block busters on the horizon. Earnings consensus going from $4.30 to $3.60 next year. | 2011-11-02 | |
| BUY | 37.220 | Mohsin Bashir | Industry could be considered a value trap. A large number of large scale pharmas are trading at depressed values because of US health reforms and patents expiring. However this one is in one of the better positions to see itself through this cycle. Have about 70 drugs, mainly in oncology, neuroscience and diabetes that they are working on in their pipeline. | 2011-06-16 | |
| DON'T BUY | 34.780 | Gordon Reid | In the same camp as many of the other big pharmas. Having trouble filling the pot. Patent expirations are taking revenue out. Good cash business with a good dividend of about 5.5%. A value trap. | 2010-05-12 | |
| DON'T BUY | 35.340 | Gordon Reid | Similar to a lot of Pharma companies in that they have to find some growth. Will have patent expiries in 2011, which will create falling sales. Looks cheap and has a great dividend but it is a shrinking situation. | 2010-03-10 | |
| BUY | 34.410 | Paul Harris, CFA | 2 issues that face phama stocks: one is health care and what will happen; and two is that the pipeline of fantastic drugs has slowed down. Treat it as a high dividend paying company and not look for huge increases in stock price. | 2010-02-18 | |
| BUY | 32.980 | Charles Bobrinskoy | All the pharmaceutical stocks are cheap. He would recommend Johnson & Johnson (JNJ-N) and Merck & Co. (MRK-N) ahead of this one. (See Top Picks.) | 2009-06-16 | |
| DON'T BUY | 35.850 | Greg A. Taylor, CFA, BBA | Pharma is a sector that usually outperforms in times of crisis and in bear markets. They have generally been a good hiding spot. The group will probably lag any uptick in the market. 5.5% dividend. | 2009-05-07 | |
| BUY | 56.980 | Ian Nakamoto | One of the major concerns that pharmacy companies have is patent expiration and generics coming in. Doesn't think they have any major products coming off patents until 2010. | 2006-11-07 | |
| BUY | 56.010 | Norman Levine | Hasn't gone anywhere because it hasn't any blockbuster drugs. Has a good pipeline. Demographically, diabetes is set to explode. | 2006-10-31 | |
| HOLD | 56.970 | Laura Wallace | Eli Lilly is a good company. It looks fine. It has come down with the other large cap drug stocks in the States. Need to be patient. It offers decent value here. | 2006-03-15 | |
| DON'T BUY | 53.500 | David Burrows | This is a part of the market that's lagging. There has been such a slowdown in the growth rates. | 2005-08-25 | |
| DON'T BUY | 56.370 | David Burrows | Prefers others such as Abbott Labs (ABT-N). | 2005-07-13 | |
| WEAK BUY | 59.750 | David Burrows | Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics. | 2005-05-03 | |
| BUY | 52.700 | George Loughery | A little bit of risk in a 3/6 month view as to whether they can retain their patent on Sprizecta (?), but the longer term they have the best drug pipeline and growth in the sector. OK for a long term hold. | 2005-03-15 | |
| TOP PICK | 61.570 | Samuel D. Isaly | Lots of new products. Rapid profit growth. | 2004-08-13 | |
| TOP PICK | 66.300 | Alan Blake | Powerful balance sheet. | 2004-07-16 | |
| TOP PICK | 72.450 | Richard Bernstien | 2004-04-16 | ||
| DON'T BUY | 78.740 | Joe Connolly | Has a very good pipeline. Getting more competition from generic drugs. Too focused on Prozac. | 2002-04-02 | |
| BUY | 81.540 | David Burrows | Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot | 2001-12-10 | |
|
| |||||
| DON'T BUY | 77.270 | Neil Murdock | Some of their drugs are coming off patent and others not doing as well. Prefers Pfizer or J & J. | 2001-10-30 | |
| HOLD | 77.200 | Brad Willock | Good pipeline for new drugs but prefers Pfizer. | 2001-09-10 | |
| DON'T BUY | 88.100 | Ross Healy | Prozac about to go generic. | 2001-06-05 |
